Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoic Acid in ALS
NCT04518540Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of alpha-lipoic acid in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 21 weeks. Status: unknown.
02
Drugs
alpha-lipoic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04518540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518540.